Mereo BioPharma Group plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MREO research report →
Companywww.mereobiopharma.com
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism.
- CEO
- Denise Vera Scots-Knight
- IPO
- 2019
- Employees
- 36
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $39.09M
- P/E
- -1.10
- P/S
- 78.18
- P/B
- 1.15
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 12.50%
- Op Margin
- -7531.06%
- Net Margin
- -7139.75%
- ROE
- -81.25%
- ROIC
- -109.06%
Growth & Income
- Revenue
- $500.00K · 0.00%
- Net Income
- $-41,878,000 · 3.18%
- EPS
- $-0.26 · 11.11%
- Op Income
- $-38,257,000
- FCF YoY
- 7.58%
Performance & Tape
- 52W High
- $3.05
- 52W Low
- $0.20
- 50D MA
- $0.31
- 200D MA
- $1.15
- Beta
- 0.19
- Avg Volume
- 1.87M
Get TickerSpark's AI analysis on MREO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 26 | Jacquet Pierre | other | 106,848 |
| Feb 26, 26 | Jacquet Pierre | other | 66,000 |
| Feb 26, 26 | Yoskowitz Marc J | other | 96,163 |
| Feb 26, 26 | Yoskowitz Marc J | other | 66,000 |
| Feb 26, 26 | Shames Daniel | other | 96,163 |
| Feb 26, 26 | Shames Daniel | other | 66,000 |
| Feb 26, 26 | Ekblom Anders | other | 133,560 |
| Feb 26, 26 | Ekblom Anders | other | 66,000 |
| Feb 26, 26 | Bender Jeremy | other | 117,533 |
| Feb 26, 26 | Bender Jeremy | other | 66,000 |
Our MREO Coverage
We haven't published any research on MREO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MREO Report →